COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)

Sponsor
National Institutes of Health Clinical Center (CC) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT04595773
Collaborator
(none)
90
1
2
35.3
2.6

Study Details

Study Description

Brief Summary

Background:

People who are recovering from COVID-19 may continue to have problems that affect their daily life. For instance, they might feel overly tired. Researchers want to learn if exercise can help people recover after COVID-19 infection.

Objective:

To study if participation in a rehabilitation exercise program can help people recovering from COVID-19.

Eligibility:

Adults ages 18-80 with a lab-confirmed SARS-CoV2 infection (the virus that causes COVID-19), and are still having some symptoms.

Design:

Participants will have a medical history and physical exam. They will give blood and urine samples. They will have tests to measure heart and lung function. Their blood vessels will be assessed.

Participants will have a computed tomography scan of the body. They will have an ultrasound of the muscles in their arms, legs, and chest.

Participants will take a 6-minute walk test. They will take other balance and movement tests.

Participants will walk on a treadmill while hooked up to a monitor. Then they will be interviewed. It will be audio-recorded.

Participants will complete surveys about their symptoms and daily activities.

Participants will take a smell test. For this, they will identify different smells. They will also have memory, attention, and mental functioning tests.

Participants will wear an activity monitor on their wrist 24 hours a day. They will exercise 3 times a week for 10 weeks by moving vigorously on a track or treadmill for 30 minutes. They will attend education classes once a week for 10 weeks.

Participants will be contacted by phone or email every 3 months for 1 year after they complete the exercise part of the study. They will wear an activity monitor for up to 2 weeks.

Condition or Disease Intervention/Treatment Phase
  • Other: Aerobic Exercise Training
  • Other: Education
Phase 1/Phase 2

Detailed Description

Study Description:

This randomized controlled trial will determine whether aerobic exercise training has a beneficial effect on physical function, health-related quality of life, free-living physical activity and sleep quality among survivors of COVID-19. Participants will be randomized to either an aerobic exercise training and education (AET+) group or a control education only group (CON) for 10 weeks. Assessments for physical function, self-reported health outcomes for quality of life (QOL), free-living physical activity and sleep quality will be measured at baseline and following the 10-week intervention period. Participants in the CON group will then crossover and perform AET after the 10-week follow-up visit. All participants will be monitored for one year to capture free-living physical activity, sleep quality and health-related QOL outcomes over time. It is hypothesized that following 10 weeks, physical function, health-related QOL, free-living physical activity and sleep quality will show greater improvement with AET+.

Objectives:
Primary Objective:

To examine the effect of aerobic exercise training on physical function in participants recovering from COVID-19.

Secondary Objectives:

To examine the effect of aerobic exercise training on patient reported outcomes and other health-related QOL components in participants recovering from COVID-19; To examine the effect of aerobic exercise training on free-living physical activity and sleep quality in participants recovering from COVID-19.

Exploratory Objectives:

To explore the effect of aerobic exercise training on clinical outcomes, cardiorespiratory function, cognition, biomarkers, metabolomics, ultrasound-based muscle measurements, and vascular function in participants recovering from COVID-19; To explore the feasibility of conducting the AET program remotely in the crossover CON group of participants recovering from COVID-19; To explore follow-up physical activity, sleep quality and health-related QOL outcomes over 1 year in participants recovering from COVID-19.

Endpoints:
Primary Endpoints:

Physical function as measured by distance walked during the 6 minute walk test after 10 weeks post randomization with AET+ and CON.

Secondary Endpoints:

Patient-reported outcomes and other health-related components after 10 weeks post-randomization with AET+ and CON; Freeliving physical activity and sleep quality after 10 weeks post-randomization with AET+ and CON.

Exploratory Endpoints:

Clinical outcomes, cardiorespiratory function, cognition, biomarkers, metabolomics, ultrasound-based muscle measurements, and vascular function after 10 weeks post-randomization with AET+ and CON; Collection of initial feasibility data to conduct exercise sessions remotely; Explore relationships between the physiological variables and post-study health outcome variables over time.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE): A Randomized Controlled Trial
Actual Study Start Date :
Jan 22, 2021
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Aerobic Exercise Training and Education (AET+)

Participants will perform both exercise training and education for 10 weeks

Other: Aerobic Exercise Training
Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.

Other: Education
Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.

Other: Education only (CON)

Participants will perform only education for the first 10 weeks, then cross-over to perform exercise in the second 10 weeks

Other: Aerobic Exercise Training
Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.

Other: Education
Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.

Outcome Measures

Primary Outcome Measures

  1. 6 minute walk test distance [Baseline, 10 weeks, 20 weeks (for cross-over group)]

    The 6MWT distance has been used to reflect longitudinal changes in physical function among patients with acute lung disease and SARS. A minimal important difference (MID) has yet to be established among survivors of COVID-19. We will consider 30 meters as the MID for this study based on reported ranges of 20 to 30 meters in patients with lung disease.

Secondary Outcome Measures

  1. Patient reported outcomes and quality of life [Baseline, 10 weeks, 20 weeks (for cross-over group), every 3 months for 1 year after exercise]

    Patient reported outcomes related to fatigue, sleep, post-traumatic stress disorder, depression, anxiety, general and COVID-19 specific QOL outcomes will be captured.

  2. Free-living physical activity and sleep quality [Baseline, 10 weeks, 20 weeks (for cross-over group), every 3 months for 1 year after exercise]

    Quantification of free-living physical activity and sleep quality and patterns using wearable accelerometer device.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
  • INCLUSION CRITERIA:

Screening procedures will be performed as part of this study. In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Male or female, aged 18 to 80 years

  2. Previous laboratory-confirmed infection with SARS-CoV2 at least 4 weeks prior to enrollment

  3. Presence of physical limitations or significant fatigue since COVID-19 as demonstrated by:

  4. Total score less than or equal to 19 on the PROMIS short form for physical function or total score greater than or equal to 9 on the PROMIS short form for fatigue, AND

  5. Score greater than or equal to 1 on the Patient Global Rating of Flu Severity and Patient Global Assessment of Interference with Daily Activities

  6. Able to read, speak and understand English or Spanish

  7. Able to understand and willing to sign a written informed consent document

  8. Willing and able to complete study procedures

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Above normal performance (i.e, greater than or equal to 100% predicted) in the 6MWT based on normative data for gender and age (86,87)

  2. History or cardiac condition as determined by NIH cardiology to be unsafe for exercise participation (e.g. ischemic heart disease, right- or left-sided heart failure, cor pulmonale or pulmonary hypertension, dilated or hypertrophic cardiomyopathy or non-idiopathic cardiomyopathy)

  3. Significant hepatic or renal dysfunction

  4. Cancer diagnosis with evidence of metastasis or a life expectancy of less than one year

  5. History of stroke resulting in impairments in functional mobility that limits safe participation

  6. Active substance abuse including EtOH

  7. Severe psychiatric disease, not responsive to treatment or medication

  8. History of diabetes and on insulin pump therapy, or uncontrolled diabetes with HbA1c > 9.0%

  9. Pregnancy

  10. Acceptance onto a lung transplant waiting list

  11. Extreme obesity with BMI > 40 kg/m^2

  12. On medications that would influence exercise performance such as beta blockers or antiretroviral therapy

  13. Ongoing tobacco and/or nicotine product use

  14. Enrolled in another interventional clinical research trial

  15. Any other medical or health condition(s) that unduly increases the risk of exercise testing or training, affects the normal physiologic response to exercise testing or training, and/or would otherwise interfere with the ability to interpret the data as determined by the PI

Contacts and Locations

Locations

Site City State Country Postal Code
1 National Institutes of Health Clinical Center Bethesda Maryland United States 20892

Sponsors and Collaborators

  • National Institutes of Health Clinical Center (CC)

Investigators

  • Principal Investigator: Leighton Chan, M.D., National Institutes of Health Clinical Center (CC)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT04595773
Other Study ID Numbers:
  • 10000102
  • 000102-CC
First Posted:
Oct 22, 2020
Last Update Posted:
Jul 25, 2022
Last Verified:
Jul 20, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Institutes of Health Clinical Center (CC)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 25, 2022